Mustang Bio (MBIO) Non-Current Deffered Revenue (2017 - 2026)
Mustang Bio (MBIO) posted quarterly Non-Current Deffered Revenue of $150000.0 for Q1 2026, little changed year-over-year from $150000.0 in Q1 2025, and little changed quarter-over-quarter from $150000.0 in Q4 2025.
Mustang Bio (MBIO) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Mustang Bio (MBIO) has reported Non-Current Deffered Revenue for 8 consecutive years, with $150000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deffered Revenue changed 0.0% year-over-year to $150000.0; the TTM figure through Mar 2026 stood at $150000.0 (changed 0.0% YoY), while the FY2025 annual figure was $150000.0, changed 0.0% from the prior year.
- Non-Current Deffered Revenue steadied at $150000.0 in Q1 2026 per MBIO's latest filing, from $150000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $270000.0 in Q1 2022 and bottomed at $150000.0 in Q4 2024.
- Historically, Non-Current Deffered Revenue has averaged $227647.1 across 5 years, with a median of $270000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue changed 0.0% — and 2024, when it tumbled 44.44%.
- Mustang Bio's Non-Current Deffered Revenue stood at $270000.0 in 2022, then changed by 0.0% to $270000.0 in 2023, then sank by 44.44% to $150000.0 in 2024, then changed by 0.0% to $150000.0 in 2025, then changed by 0.0% to $150000.0 in 2026.
- Business Quant data shows MBIO's Non-Current Deffered Revenue at $150000.0 in Q1 2026, $150000.0 in Q4 2025, and $150000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | 150,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 150,000.00 |
| Mar 31, 2026 | 150,000.00 |
| Dec 31, 2025 | 150,000.00 |
| Sep 30, 2025 | 150,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 150,000.00 |
| Dec 31, 2024 | 150,000.00 |
| Sep 30, 2024 | 270,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 270,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 270,000.00 |
| Jun 30, 2023 | 270,000.00 |
| Mar 31, 2023 | 270,000.00 |
| Dec 31, 2022 | 270,000.00 |
| Sep 30, 2022 | 270,000.00 |
| Jun 30, 2022 | 270,000.00 |
| Mar 31, 2022 | 270,000.00 |
| Dec 31, 2021 | 270,000.00 |
| Sep 30, 2021 | 270,000.00 |